Walgreens Boots Alliance, Inc. and ADMA Biologics, Inc.: SG&A Spending Patterns Compared

SG&A Spending: Walgreens vs. ADMA

__timestampADMA Biologics, Inc.Walgreens Boots Alliance, Inc.
Wednesday, January 1, 2014482386917992000000
Thursday, January 1, 2015674596822400000000
Friday, January 1, 2016849474223910000000
Sunday, January 1, 20171809283523813000000
Monday, January 1, 20182250292224694000000
Tuesday, January 1, 20192591075723557000000
Wednesday, January 1, 20203505081725436000000
Friday, January 1, 20214289688924586000000
Saturday, January 1, 20225245802427295000000
Sunday, January 1, 20235902000034205000000
Monday, January 1, 202428113000000
ngram

SG&A Spending Patterns: Walgreens Boots Alliance vs. ADMA Biologics

In the ever-evolving landscape of healthcare, understanding the financial strategies of key players is crucial. Walgreens Boots Alliance, Inc. and ADMA Biologics, Inc. present a fascinating study in contrasts when it comes to Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Walgreens consistently outspent ADMA, with its SG&A expenses peaking at approximately $25.5 billion in 2023, a 44% increase from 2014. In contrast, ADMA's SG&A expenses grew by over 1,100% during the same period, reaching nearly $59 million in 2023. This stark difference highlights Walgreens' expansive operational scale compared to ADMA's rapid growth trajectory. Notably, Walgreens' data for 2024 shows a further increase, while ADMA's data is missing, indicating potential reporting gaps. These insights underscore the diverse financial strategies within the healthcare sector, reflecting both stability and aggressive growth.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025